Reserpine and breast cancer
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A case‐control survey of long‐term, comprehensive records from the Kaiser Foundation Medical Care Program produces a significant positive association between reserpine use and breast cancer, but the association vanishes upon further matching with respect to the year of first hypertension diagnosis and the subsequent length of follow-up.
Abstract
After a series of studies on the linkage of reserpine with breast cancer, both evidence and interpretation appeared to be in conflict. Our case-control survey of long-term, comprehensive records from the Kaiser Foundation Medical Care Program, on 108 hypertensive breast cancer cases and 324 hypertensive controls, matched by year of birth and by race, produces a significant positive association between reserpine use and breast cancer. However, the association vanishes upon further matching with respect to the year of the first hypertension diagnosis and the subsequent length of follow-up. We thus fail to support suspicions of causality.